NCT00511160

Brief Summary

Myocarditis is mainly caused by cardiotropic viruses. In recent time viruses found in endomyocardial biopsies mainly consist of parvovirus B19 (PVB19) and human herpesvirus 6 (HHV6). A definite causal link between virus-genome detection of PVB19 and/or HHV6 (via pcr techniques)and cardiac inflammation and dysfunction is however still missing. Primary objective: To determine the prevalence of PVB19 and HHV6 virus genome in heart muscle biopsies of cardiac surgery patients without clinical evidence of myocarditis or myocarditic sequelae Secondary objectives:

  1. 1.Correlation of non-invasive myocarditis screening exams (cardiac magnetic resonance, ecg, history, inflammatory markers) with biopsy results
  2. 2.Prognostic value of virus prevalence for the postoperative course

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2007

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

August 2, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 3, 2007

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

October 5, 2016

Status Verified

October 1, 2016

Enrollment Period

3 years

First QC Date

August 2, 2007

Last Update Submit

October 4, 2016

Conditions

Keywords

myocarditisparvovirus B19 (PVB19)human herpes virus 6 (HHV6)cardiac magnetic resonance tomography (CMR)

Outcome Measures

Primary Outcomes (1)

  • To determine the prevalence of PVB19 and HHV6 virus genome in heart muscle biopsies of cardiac surgery patients without clinical evidence of myocarditis or myocarditic sequelae

    2 years

Secondary Outcomes (2)

  • Correlation of non-invasive myocarditis screening exams (cardiac magnetic resonance, ecg, history, inflammatory markers) with biopsy results

    2 years

  • Prognostic value of virus prevalence for the postoperative course

    2 years

Study Arms (2)

S

ACTIVE COMPARATOR

Study arm: Cardiac surgery group

Procedure: Myocardial biopsies with TRU CUT 14 Gauge needle

C

ACTIVE COMPARATOR

Routine cardiology group

Procedure: Endomyocardial biopsies

Interventions

Myocardial needle biopsy and right atrial appendectomy

Also known as: TRU CUT 14 Gauge needle
S

The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling

C

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Cardiac surgery with cardiopulmonary bypass

You may not qualify if:

  • No ability to give informed consent
  • presence of so far accepted parvovirus/herpesvirus associated comorbidities
  • contraindications for magnetic resonance

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Robert Bosch Krankenhaus, Auerbachstrasse 110

Stuttgart, Baden-Wurttemberg, 70376, Germany

Location

MeSH Terms

Conditions

Myocarditis

Condition Hierarchy (Ancestors)

CardiomyopathiesHeart DiseasesCardiovascular Diseases

Study Officials

  • Udo P Sechtem, MD

    Head of Cardiology, Robert Bosch Krankenhaus, Stuttgart, Germany

    STUDY CHAIR
  • Ulrich FW Franke, MD

    Head of Cardiovascular Surgery, Robert Bosch Krankenhaus, Stuttgart, Germany

    STUDY DIRECTOR
  • Reinhardt Kandolf, MD

    Director of Institute of Molecular Pathology University Tuebingen, Germany

    STUDY DIRECTOR
  • Hannibal Baccouche, MD

    Department of Cardiology, Robert Bosch Krankenhaus, Stuttgart, Germany

    PRINCIPAL INVESTIGATOR
  • Hardy Baumbach, MD

    Department of Cardiovascular Surgery, Robert Bosch Krankenhaus Stuttgart, Germany

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Prof. Udo Sechtem

Study Record Dates

First Submitted

August 2, 2007

First Posted

August 3, 2007

Study Start

August 1, 2007

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

October 5, 2016

Record last verified: 2016-10

Data Sharing

IPD Sharing
Will not share

Locations